Chinese drug developer Brii Biosciences has filed an emergency use authorization (EUA) application with the US Food and Drug Administration for its SARS-CoV-2-neutralizing antibody combination therapy, the Hong Kong-listed company said on 8 October.
Coronavirus Update: Brii Files US EUA For Antibody Combo
Plus, Wider Japan Ronapreve Use Sought
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
